17th week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220125756 | THC-ALCOHOL APPARATUS AND METHOD OF MANUFACTURE THEREOF - The invention comprises a method and apparatus for forming a Cannabis product, comprising the steps of: combining tetrahydrocannabinol and ethanol to form a THC-alcohol compound, the THC-alcohol compound comprising less than fifty percent water by mass and subjecting the THC-alcohol compound to a shear force in excess of 100 or 50,000 sec | 2022-04-28 |
20220125757 | COMBINATION PRODUCT CONTAINING LIMONOID COMPOUND AND BIGUANIDE COMPOUND - The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a biguanide compound (e.g., metformin, metformin hydrochloride, buformin, and phenformin). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes, for lipid-lowering and weight-loss, and the like. | 2022-04-28 |
20220125758 | PREPARATION METHOD FOR LIPOSOME HAVING ABILITY TO STABLY ENCAPSULATE ACTIVE INGREDIENT - A preparation method for a liposome having the ability to stably encapsulate an active ingredient is provided. The preparation method includes providing a mixture and homogenizing the mixture at 300 bar-400 bar to form a liposome suspension. The mixture includes 0.1 wt % of lecithin, 2 wt %-5 wt % of Arabic gum and 63.9125 wt %-97.9 wt % of a solvent. The liposome suspension includes a plurality of liposomes. | 2022-04-28 |
20220125759 | METHODS OF INCREASING MAGNESIUM BIOAVAILABILITY AND ABSORPTION - The present disclosure relates to compositions and methods of increasing magnesium bioavailability and absorption. | 2022-04-28 |
20220125760 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) - Resistance of acute myeloid leukemia (AML) cells to DNA damaging therapeutic agents is dependent on CHK1 protein levels. Here, the inventors demonstrate that in AML, CHK1 protein stability relies on the expression and activity of Ubiquitin Specific Protease 7 (USP7). CHK1 and USP7 levels are positively correlated in AML cell lines and primary patient specimens with high CHK1 protein levels. USP7 associates with CHK1, leading to its stabilization by deubiquitinylation, and this association is enhanced in response to cytarabine treatment. Pharmacological or RNA interference-mediated inhibition of USP7 significantly reduced AML proliferation in vitro and in vivo, and increased AML cell death. It is important to note that USP7 inhibition synergized with cytarabine to kill AML cell lines. This is also the case in primary patient specimens with high CHK1 levels. Transcriptomic dataset analyses revealed that a USP7 gene signature is highly enriched in cells from AML patients at relapse, as well as in residual blasts from Patient Derived Xenograft (PDX) models treated with clinically relevant doses of cytarabine, strongly suggesting a relationship between USP7 expression and resistance to therapy. Finally, single cell analysis from AML patient at relapse versus diagnosis showed that a gene signature of the pre-existing subpopulation responsible for relapse is enriched in transcriptomes of patients with high USP7 level. Altogether, these data demonstrate that USP7 is a master regulator of CHK1 protein kinase in AML cells, and represents both a marker of resistance to chemotherapeutic treatments, as well as a potential therapeutic target to overcome treatment resistance. | 2022-04-28 |
20220125761 | COMPLEX, CONTRAST AGENT AND METHOD FOR TREATING A DISEASE RELATED TO CXCR4 RECEPTOR - Disclosed herein is a complex, a contrast agent and the method for treating a disease related to CXCR4 receptor. The complex is configured to bind the CXCR4 receptor, and is used as a medicament for diagnosis and treatment of cancers and other indications related to the CXCR4 receptor. | 2022-04-28 |
20220125762 | SMALL MOLECULE ANTAGONIST TO PACAP RECEPTOR AND USES THEREOF - The invention relates to compounds that demonstrate efficacy in blocking PACAP receptors (e.g. PAC1) and associated methods of treating neurological diseases or disorders using the disclosed compounds. The neurological diseases or disorders include, but are not limited to, stress-related diseases (e.g. chronic stress, post-traumatic stress disorder (PTSD), anxiety, or general anxiety disorder), pain-related diseases (e.g. chronic pain, primary headache disorders, or migraines), or addiction (e.g. addiction to a substance (e.g. addiction to cocaine, amphetamines, methamphetamine, methylphenidate, nicotine, alcohol, prescription medication, marijuana, tobacco, or an opioid selected from heroin, fentanyl, codeine, hydrocodone, morphine, oxycodone, hydromorphone, and methadone)). | 2022-04-28 |
20220125763 | COMPOSITIONS PROVIDING ENHANCED ANTIBACTERIAL ACTIVITY AGAINST GRAM-POSITIVE BACTERIA AND USE THEREOF - A method of inhibiting, reducing growth of or destroying gram positive bacteria comprising contacting the gram positive bacteria with an effective amount of a 2-(substituted-amino)-imidazole compound and with an additional antibacterial compound separately, simultaneously, or sequentially, whereby the two compounds provide an antibiotic potentiation effect against the gram-positive bacteria. The additional antibacterial compound may comprise penicillin, daptomycin, vancomycin, oxacillin, linezolid, or a related antibiotic(s). | 2022-04-28 |
20220125764 | PHARMACEUTICAL COMPOSITION COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND - The present invention relates to a pharmaceutical composition for preventing the recurrence of gastroesophageal reflux disease, comprising a benzimidazole derivative. The pharmaceutical composition of the present invention may effectively prevent the recurrence of gastroesophageal reflux disease without any side effects for a long period of time. | 2022-04-28 |
20220125765 | PHARMACEUTICAL COMBINATIONS COMPRISING MEBENDAZOLE AND A STRONG OR MODERATE CYP1A2 INHIBITOR - The invention relates to a pharmaceutical composition comprising mebendazole and a strong or moderate cytochrome P | 2022-04-28 |
20220125766 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION - The present disclosure relates generally to compounds and pharmaceutical compositions for increasing glycosylation and treating congenital disorders of glycosylation. | 2022-04-28 |
20220125767 | THIAZOLIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS - Thiazolide compounds, such as nitazoxanide and/or tizoxanide, may be used against viruses belonging to the Picornaviridae family or the Paramyxoviridae family. | 2022-04-28 |
20220125768 | TARGETING RNA VIRUSES USING INHIBITORS OF METTL3 - Provided are methods for prophylaxis or therapy for an RNA virus infection. The methods involve modulating the Type I interferon pathway in RNA virus infected cells of an individual. The Type I interferon pathway is modulated by administering one or more agents to virus infected cells that inhibit the expression and/or function of METTL3 or inhibit expression and/or function of YTHDF1, YTHDF2 or YTHDF3. | 2022-04-28 |
20220125769 | ESTROGEN RECEPTOR MODULATORS FOR TREATING MUTANTS - Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ERα). | 2022-04-28 |
20220125770 | COMBINATION THERAPY OF ALK-POSITIVE NEOPLASIA - The invention relates to a pharmaceutical product comprising therapeutically effective amounts of:
| 2022-04-28 |
20220125771 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME - The present invention includes substituted polycyclic carboxylic acids, analogues thereof, and compositions comprising the same, which can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) in a patient. In certain embodiments, the invention provides a compound of formula (I), or a salt, solvate, geometric isomer, stereoisomer, tautomer, and any mixtures thereof: | 2022-04-28 |
20220125772 | A2A ANTAGONISTS AS COGNITION AND MOTOR FUNCTION ENHANCERS - Methods are described for inducing cognition and motor function enhancement in patients suffering from Parkinson's disease by administering an effective amount of an Adenosine 2a antagonist. The Adenosine 2a antagonist can optionally be administered in combination with a dopamine precursor, such as levodopa, or a dopamine receptor agonist. | 2022-04-28 |
20220125773 | AQUEOUS FORMULATIONS OF WATER INSOLUBLE COX-2 INHIBITORS - Described herein are compositions and methods for treatment with aqueous formulations of water insoluble COX-2 inhibitors and a solubilizing agent. | 2022-04-28 |
20220125774 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES - Compounds and methods are provided for the treatment of neurological or mitochondrial diseases, including epilepsy. In some embodiments, the compounds are substituted 1,4-naphthoquinones. | 2022-04-28 |
20220125775 | METHODS OF TREATING HIDRADENITIS SUPPURATIVA - Provided herein are methods for treating a subject suffering from a cutaneous neutrophilic inflammatory disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I | 2022-04-28 |
20220125776 | Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure - Provided herein are various regimens for treating acute myeloid leukemia (AML) in subjects (e.g, patients) who have undergone one or more prior anti-AML therapies involving venetoclax, and have shown disease progression after the one or more prior therapies. The treatment regimens disclosed herein involve alvocidib, either as a monotherapy, or in combination with cytarabine or a hypomethylating agent, such as decitabine or azacitidine. The treatment regimens disclosed herein do not involve combination therapy of alvocidib with venetoclax. | 2022-04-28 |
20220125777 | COMBINATION OF A CDK INHIBITOR AND A PIM INHIBITOR - This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor, in particular a CDK4/6 inhibitor, and a proviral integration site for Moloney murine leukemia virus (PIM) inhibitor, and associated pharmaceutical compositions, methods of treatment, and uses. | 2022-04-28 |
20220125778 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING BETA-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA - The present disclosure describes compounds and compositions that inhibit β-glucuronidase activity, and methods for attenuating the side effects of one or more drugs and improving the efficacy of drugs by administration of selective β-glucuronidase inhibitors. | 2022-04-28 |
20220125779 | Compositions and Methods for Treating Traumatic Brain Injury - Certain embodiments are directed to methods and compositions for treating or preventing seizures in a subject using a therapeutic agent comprising one or more Transient Receptor Potential-Canonical 4/5 channel antagonists sufficient to regulate excitability of neurons in the brain of a subject. | 2022-04-28 |
20220125780 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS - The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORγ modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor. | 2022-04-28 |
20220125781 | Methods and Compositions for Treating Vasomotor Symptoms - The present disclosure is generally directed to compositions and methods for treating or limiting development of vasomotor symptoms in a subject. | 2022-04-28 |
20220125782 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES - A technique of administering rifampicin over an extended period of time, with reduced side effects. A medicine that is for nasal administration and is used to prevent or treat neurodegenerative diseases, contains a rifampicin selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and a resveratrol selected from resveratrol and derivatives thereof, has reduced side effects, and can be administered over an extended period of time. | 2022-04-28 |
20220125783 | COMPOSITIONS AND METHODS OF USING NINTEDANIB FOR TREATING OCULAR DISEASES WITH ABNORMAL NEOVASCULARIZATION - Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed. | 2022-04-28 |
20220125784 | METHODS AND COMPOUNDS FOR INHIBITION OF INACTIVATION OF VOLTAGE-GATED SODIUM CHANNELS - The current application relates to compounds that bind and inhibit the inactivation of Navi.5 voltage-gated sodium channel (VGSC). The compounds can be used for treating cardiovascular diseases such as Brugada syndrome, cardiac arrhythmia disorder, progressive cardiac conduction disorder (PCCD), sick sinus syndrome, progressive familial block, atrial fibrillation, sudden infant death syndrome, dilated cardiomyopathy, myocardial ischemia/infarction, or heart failure. | 2022-04-28 |
20220125785 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF - The present invention belongs to the pharmaceutical field, and provides crystalline forms, solvates and the crystalline forms thereof of the compound (S)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazin-7-yl)ethyl)amino)pyrimidine-5-carbo nitrile, and the pharmaceutical compositions comprising the same as well as the methods of preparing the same and the use thereof. | 2022-04-28 |
20220125786 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION - Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation. | 2022-04-28 |
20220125787 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY - This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension. | 2022-04-28 |
20220125788 | FAK inhibitor and drug combination thereof - A deuterated compound as represented by formula (I) or an optical isomer, a tautomer, a pharmaceutically acceptable salt, a prodrug, a hydrate, or a solvate thereof are presented. Compared with a compound before deuteration, the deuterated compound shows better pharmacokinetics, higher maximum plasma drug concentration, higher exposure, and longer half-life, and has more excellent metabolic performance. The deuterated compound can effectively inhibit FAK activity, and has good application prospect in preparation of FAK inhibitors and/or drugs for treating cancer. In addition, the use of the deuterated compound in combination with an anti-cancer drug (such as a PD-1 inhibitor) can achieve a synergistic effect, thereby significantly improving the tumor suppression effect, and providing a better choice for clinical cancer treatment. | 2022-04-28 |
20220125789 | PHARMACEUTICAL PREPARATION OF FRUQUINTINIB AND USE THEREOF - A pharmaceutical composition of fruquintinib comprising filler and its preparing process are disclosed. The filler is selected from starch, microcrystalline cellulose or a combination thereof. The composition is in the form of a tablet or capsule and can be used in the treatment of cancer, such as colorectal cancer, non-small cell lung cancer, and gastric cancer. | 2022-04-28 |
20220125790 | MULTI-TARGET KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD FOR MULTI-TARGET KINASE INHIBITOR AND USE THEREOF - A multi-target kinase inhibitor is shown in formula (I), in which R is selected from formula (a), formula (b), formula (c), formula (d), formula (e) and formula (f). The multi-target kinase inhibitor can effectively inhibit the enzymatic activities of RET, VEGFR3 and PDGFRA, and can effectively treat diseases that are regulated and controlled by multi-target kinases and are related to abnormal signal transduction pathways of the multi-target kinases, including cancers of breast, respiratory tract, brain, reproductive organ, digestive tract, urinary tract, eye, liver, skin, head and/or neck and distant metastatic cancers thereof, and lymphoma, sarcoma, leukemia and the like. The active ingredients of the pharmaceutical composition of the present invention comprise a multi-target kinase inhibitor, which accounts for 1-50 wt % of the composition. | 2022-04-28 |
20220125791 | NOVEL DEVICES - Disclosed herein are novel drug eluting contact lenses configured to release one or more compounds that inhibit phosphodiesterase 1 (PDE1). The PDE1 inhibitors may be administered as monotherapy or in combination with additional pharmaceutical agents in the treatment of an ophthalmic disease, disorder or injury. Related methods of use and treatment are also disclosed. | 2022-04-28 |
20220125792 | USE OF COMPOSITION CONTAINING CDK4/6 INHIBITOR IN COMBINATION WITH ANASTROZOLE IN PREPARATION OF MEDICAMENT FOR TREATING TUMOR DISEASES - The present disclosure relates to use of a composition containing a CDK4/6 inhibitor in combination with anastrozole in preparation of a medicament for treating tumor diseases. Specifically, the CDK4/6 inhibitor involved in the application is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. | 2022-04-28 |
20220125793 | CANCER THERAPY USING 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND AND IMMUNE CHECKPOINT INHIBITOR - The problem to be solved by the present disclosure is to provide a novel combination therapy using (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof, the combination therapy exhibiting an excellent antitumor effect on cancer patients with resistance to immune checkpoint inhibitors. The present disclosure provides an antitumor agent comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof as an active ingredient, the antitumor agent being administered in combination with an immune checkpoint inhibitor, except for pembrolizumab, to a cancer patient with resistance to immune checkpoint inhibitors. | 2022-04-28 |
20220125794 | COMBINATION THERAPIES - Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable form thereof, and a Bcl-2 inhibitor or a pharmaceutically acceptable form thereof. Also provided herein are methods for treating cancer comprising administration the compositions, and uses of the compositions, e.g., for the treatment of cancer. | 2022-04-28 |
20220125795 | THERAPEUTIC COMBINATIONS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to pharmaceutical combinations of at least one thiopurine and/or at least a pharmaceutically acceptable salt and/or at least one prodrug thereof and riboflavin to treat patients suffering from inflammatory bowel disease (IBD) or other inflammatory conditions. This invention also relates to additive and/or combinations of at least one thiopurine and riboflavin. This invention is also related to a method for the treatment or prophylaxis of IBD or other inflammatory conditions, which method comprises administering a therapeutically effective amount of thiopurine and riboflavin. | 2022-04-28 |
20220125796 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT - A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 2022-04-28 |
20220125797 | SALTS AND SOLID FORMS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDIN- E-2,6-DIONE AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME - Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed. | 2022-04-28 |
20220125798 | READY-TO-USE INJECTABLE FORMULATIONS - The invention describes a ready-to-use injectable cephalosporin composition with reasonable viscosity, resuspendability, and syringeability attributes for injection as an antibiotic for animals. | 2022-04-28 |
20220125799 | METHODS OF TREATING 4-REPEAT TAUOPATHIES - The present invention relates to the treatment patient with a 4-repeat (4R) tauopathy using a therapeutically effect amount of a rho kinase inhibitor. One preferred inhibitor is fasudil and preferred methods involve the daily oral administration of between 20 and 250 mg of fasudil. Preferred 4R tauopathies treatable according to the invention include progressive supranuclear palsy with Richardson syndrome (PSP-RS) and corticobasal syndrome with probable sporadic corticobasal degeneration. | 2022-04-28 |
20220125800 | TREATMENT OF CANCER AND INHIBITION OF METASTASIS - Compounds and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. | 2022-04-28 |
20220125801 | OPHTHALMIC COMPOSITION OF BIMATOPROST - The present invention relates to an ophthalmic composition comprising bimatoprost or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. It further relates to a method of preparing such compositions and their use for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. | 2022-04-28 |
20220125803 | METHODS FOR THE TREATMENT OF PERIMENOPAUSE AND MENOPAUSE - The invention relates to methods of treating the symptoms of perimenopause or menopause using positive allosteric modulators γ-aminobutyric acid type A (GABA-A PAMs) receptor, including 3α-hydroxy-3β-mnethoxymethyl-21-(1′-imidazolyl)-5α-pregnan-20-one and salts thereof. | 2022-04-28 |
20220125804 | SUPPLEMENTS CAPABLE OF ADDRESSING SIDE EFFECTS OF PRESCRIPTION DRUGS - A nutritional supplement formulated for use in conjunction with a particular prescription drug includes a combination of ingredients that addresses a combination of side effects of the prescription drug. The ingredients of the nutritional supplement may address all treatable very common side effects and/or common side effects of the prescription drug or the ingredients may address treatable serious side effects of the prescription drug. Nutritional supplement-prescription drug combinations that reduce or prevent the occurrence of side effects are also disclosed, as are methods for treating the side effects of prescription drugs with nutritional supplements. | 2022-04-28 |
20220125805 | BIOLOGICALLY ACTIVE GANODERMA LUCIDUM COMPOUNDS AND SYNTHESIS OF ANTICANCER DERIVATIVES; ERGOSTEROL PEROXIDE PROBES FOR CELLULAR LOCALIZATION - The bioactive compounds of | 2022-04-28 |
20220125806 | STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME - A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation can comprise one or both of 25-hydroxyvitamin D | 2022-04-28 |
20220125807 | PHARMACEUTICAL COMBINATION OF WNT SIGNALING AND MACC1 INHIBITORS - A pharmaceutical combination, includes an inhibitor of the Wnt/β-catenin signaling pathway and an inhibitor of MACC1. One combination includes an inhibitor of S100A4 as a Wnt-signaling inhibitor, preferably niclosamide, and a statin or MEK1 inhibitor as an inhibitor of MACC1. A pharmaceutical composition can include the combination. The combination or composition can be used in the treatment of a tumor disease, such as a solid tumor, and/or for the treatment and/or prophylaxis of tumor metastasis. | 2022-04-28 |
20220125808 | LIPID COMPOSITIONS WITH HIGH DHA CONTENT - The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like. | 2022-04-28 |
20220125809 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH - Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from | 2022-04-28 |
20220125810 | THC CONTAINER APPARATUS AND METHOD OF USE THEREOF - The invention comprises a method and apparatus for holding a | 2022-04-28 |
20220125811 | INJECTABLE COMPOSITION FOR INDUCING LIPOLYSIS AND METHOD USING THE SAME - Provided is an injectable composition for inducing lipolysis with less pain when injected. Since the composition has an osmolarity within an appropriate range and has a neutral pH, pain at the time of injection of the composition is very small. Also, as a large amount of drug is injected during one treatment, the lipolytic effect is excellent, and local fat removal is possible in a short period of time. The composition may be used safely without side effects. Therefore, the composition may be used in a method for inducing lipolysis. | 2022-04-28 |
20220125812 | COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF - The present invention relates to pharmaceutical compositions containing boron-containing compounds and their use as inhibitors of beta-lactamase enzymes and as antibacterial agents in combination with a beta-lactam antibiotic. | 2022-04-28 |
20220125813 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents. | 2022-04-28 |
20220125814 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR - Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor in combination with a nicotinamide adenine dinucleotide (NAD) salvage pathway precursor are described. Cancers treated with the combination therapies can be nicotinamide riboside kinase (NMRK1) low cancers and/or Myc high cancers and can include various forms of glioblastomas. | 2022-04-28 |
20220125815 | SYNERGISTIC BIOACTIVE COMPOSITIONS FOR ENHANCING CELLULAR ENERGY - The present invention relates to synergistic bioactive compositions for enhancing cellular energy in aerobic or anaerobic conditions. Particularly, the invention relates to a synergistic bioactive composition comprising specific combination of purine nucleoside and hydrophilic pyridinecarboxamide compound(s) which are present in the ratio of 1:0.1 to 1:1 along with pharmaceutically acceptable carriers/excipients, wherein ‘purine nucleoside’ is inosine adduct and the hydrophilic pyridinecarboxamide compound is selected from nicotinamide riboside or nicotinamide mononucleotide either alone or in combination thereof. Further, the present cellular energy enhancing bioactive compositions are useful for treating ATP deficiency conditions. Moreover, the composition is useful for treating hepatic dysfunctions. | 2022-04-28 |
20220125816 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUD - Provided herein are methods to improve transport or uptake of an avermectin compound in a cell or tissue expressing an efflux transporter P-glycoprotein (Pgp) by co-administering an effective amount of the avermectin compound and a Ppg inhibitor to the cell or tissue. The method also provides improved efficiency transport or uptake of an avermectin compound in the cell or tissue. The methods can be used therapeutically to treat Alcohol Use Disorder. | 2022-04-28 |
20220125817 | PHARMACEUTICAL COMPOSITIONS FOR DEMODEX RELATED BLEPHARITIS AND EYELID CRUSTING - Formulation of ectoparasiticidal and antibiotic “compositions into pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eye crusting. | 2022-04-28 |
20220125818 | COMPOSITIONS AND METHODS FOR TREATMENT OF A CORONAVIRUS DISEASE (COVID-19) INFECTION - Compositions and methods for treating COVID-19 infections are provided herein. The methods include administering a therapeutically effective amount of a combination of at least three components. The first component is selected from a group consisting of azithromycin, doxycycline, and remdesivir, the second component is selected from a group consisting of hydroxychloroquine and a corticosteroid, and the third component is selected from a group consisting of acetylsalicylic acid, rivaroxaban, clopidogrel, and enoxaparin sodium. | 2022-04-28 |
20220125819 | METHODS OF PREVENTING AND TREATING COVID-19 INFECTION - A product for preventing COVID-19 infection in an individual, the product comprising a combination of hydroxychloroquine, vitamin C, vitamin D, and zinc. The combination comprises 1,000 mg to 10,000 mg of vitamin C, 3,000 IU to 40,000 IU of vitamin D, and 25 mg to 75 mg of zinc. The combination is administered daily for two or more days for prophylaxis, or the combination is administered weekly over a period of two or more weeks for prophylaxis. | 2022-04-28 |
20220125820 | DRUG FORMULATIONS FOR CANCER TREATMENT - Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect. | 2022-04-28 |
20220125821 | CYCLIC DINUCLEOTIDE PRODRUG MOLECULE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - Disclosed are a cyclic dinucleotide prodrug molecule, a preparation method therefor and an application thereof relating to the field of pharmaceuticals. The cyclic dinucleotide prodrug molecule has a structure shown in formula I, II, or III, can freely cross cell membranes and release cyclic dinucleotide, and has high cell activity. | 2022-04-28 |
20220125822 | Treatment Methods for Fibrosis Targeting SMOC2 - Described herein are methods for treating fibrosis, e.g., kidney fibrosis, using agents that target Secreted Modular Calcium-binding protein 2 (SMOC2). | 2022-04-28 |
20220125823 | EXTRAHEPATIC DELIVERY - The invention relates to a method of gene silencing, comprising administering to a cell or a subject in need thereof a therapeutically effective amount of the lipophilic moieties-conjugated double-stranded iRNAs at one or more internal positions on at least one strand, optionally via a linker or carrier. | 2022-04-28 |
20220125824 | COMPOSITIONS AND METHODS FOR TREATING CANCER - Provided are nucleic acid constructs and systems which comprise (i) a first nucleic acid construct encoding a toxin operatively linked to a first promoter and at least one cancer-associated signaling responsive enhancer element; and (ii) a second nucleic acid construct encoding an anti-toxin operatively linked to a second promoter, the second promoter being stronger than the first promoter. | 2022-04-28 |
20220125825 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS - Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound. | 2022-04-28 |
20220125826 | Synergism of GOS and polyfructose - The present invention relates to the field of prebiotics. Provided are uses for compositions comprising synergistically effective amounts of polyfructose and galactooligosaccharides (GOS). | 2022-04-28 |
20220125827 | Application of Sulfated Polysaccharides in Resisting novel Coronavirus - The disclosure provides application of sulfated polysaccharides in resisting novel coronavirus, belonging to the technical field of biomedicine. It is confirmed in the disclosure that by binding to an S protein on the surface of the SARS-CoV-2 virus, the sea cucumber polysaccharides, fucoidans or carrageenans can prevent cell membranes of body cells from adsorbing and internalizing the SARS-CoV-2 virus, thereby preventing the SARS-CoV-2 virus from infecting the body cells, which indicates that the sea cucumber polysaccharides, fucoidans or carrageenans have the effect of prevention and treatment of pneumonia caused by the novel coronavirus. These polysaccharides can be used to prepare protective articles having functions of prevention and treatment of novel coronavirus infection, for example: inhalations, hand lotions, oral liquids and respirators. | 2022-04-28 |
20220125828 | ANTISEPTIC POLYMER AND SYNTHESIS THEREOF - According to the present invention there is provided a polymer comprising at least one antiseptic/analgesic/anti-inflammatory monomeric unit in conjunction with at least three further monomeric units, said three further monomeric units eliciting properties selected from the group consisting of temperature activation, water solubility, mechanical strength, protein/polysaccharide bonding capacity, and combinations thereof. In particular, disclosed herein is a polymer, wherein the water-soluble monomeric unit is a hydrophilic ethylene glycol (OEGMA) moiety: the mechanical strength-conferring monomeric unit is polylactide-co-2-hydroxy-ethyl-methyl acrylate (PLA/HEMA); the protein-reactive monomeric unit is an N-acryloxysuccinimide (NAS) moiety; and the thermosetting monomeric unit is an N-isopropyl acrylamide (NIPAAm) moiety. The anti-septic/analgesic/anti-inflammatory monomeric unit comprises a methacrylic ester derivative of salicylic acid (5-HMA or 4-HMA, or a combination thereof). | 2022-04-28 |
20220125829 | METHODS AND COMPOSITIONS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION, DRY EYE DISEASE, AND RELATED DISORDERS - The invention provides methods, compositions, and kits containing a pharmaceutical composition, for treating meibomian gland dysfunction, dry eye disease, and related disorders. | 2022-04-28 |
20220125830 | INDUCING CASPASE ACTIVITY - Embodiments are directed towards methods of inducing caspase activity. The methods include contacting a cell with a treatment compound formed by alkoxylation of an initiator using an oxide. | 2022-04-28 |
20220125831 | REGENERATIVE CO2 TREATMENT SYSTEM AND METHOD - The present technology provides regenerative treatment methods and apparatus to stimulate hair growth. Regenerative treatments to stimulate hair growth include the subcutaneous application of carbon dioxide, and may also include suction, energy input, and topical application of nutrients to a patient's scalp. Regenerative treatment methods include an initial treatment phase and a maintenance treatment phase. | 2022-04-28 |
20220125832 | USE OF PRUSSIAN BLUE NANOPARTICLES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION, DELAY OR TREATMENT OF NEURODEGENERATIVE DISEASE - The present application relates to use of Prussian blue nanoparticles in the preparation of a medicament for the prevention, delay or treatment of neurodegenerative disease. The present application finds that Prussian blue nanoparticles have significant effects in the prevention, delay or treatment of neurodegenerative disease. Cell test results show that Prussian blue nanoparticles can reduce the level of ROS in nerve cells stimulated by hydrogen peroxide and increase the proportion of living cells in nerve cells stimulated by hydrogen peroxide. Animal test results show that Prussian blue nanoparticles can significantly reduce the expression level of oxidative stress markers in the hippocampus of mouse models of neurodegenerative disease, and significantly improve the learning and memory abilities and ameliorate motor dysfunction of mouse models of neurodegenerative disease. Prussian blue nanoparticles have advantages of simple preparation process, easy for large scale production, mild reaction conditions and easy for surface modification. | 2022-04-28 |
20220125833 | VITAMIN D COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF COVID-19 AND OTHER LIPID ENVELOPED VIRAL INFECTIONS - Vitamin D formulations and method of administering the same for COVID-19 patients. | 2022-04-28 |
20220125834 | LOCALIZED DELIVERY OF THERAPEUTIC AGENTS - The present invention is directed to compositions and methods for the prevention or treatment of diseases or conditions, including heterotopic ossification, vascular calcification, or pathologic calcification involving methods of drug delivery that allow soft tissue to be treated without interfering with normal processes of bone formation or calcification. | 2022-04-28 |
20220125835 | SILICIFIED IMMUNOGENIC CELLS, METHODS OF MAKING, AND METHODS OF USING - A pharmaceutical composition includes a silicified cell or fraction thereof, a cationic layer disposed on at least a portion of the surface of the silicified cell or fraction thereof, and an immunomodulatory moiety bound to at least a portion of the cationic layer. Alternatively, the pharmaceutical composition includes a silicified cell or fraction thereof, a cationic layer disposed on at least a portion of the surface of the silicified cell or fraction thereof, an anionic layer disposed on at least a portion of the cationic layer, and an immunomodulatory moiety bound to at least a portion of the anionic layer. | 2022-04-28 |
20220125836 | TREATMENT INVOLVING CAR-ENGINEERED T CELLS AND CYTOKINES - The present disclosure relates to methods and agents for enhancing the effect of T cells engineered to express chimeric antigen receptors (CARs). These methods and agents are, in particular, useful for the treatment of diseases characterized by diseased cells expressing an antigen the CAR is directed to. Specifically, the present disclosure relates to methods comprising providing to a subject T cells genetically modified to express a chimeric antigen receptor (CAR) and administering to the subject IL2 or a polynucleotide encoding IL2. The methods of the disclosure may comprise administering IL2 or a polynucleotide encoding IL2 and a further cytokine or a polynucleotide encoding a further cytokine, wherein the further cytokine may be IL7 or IL21. The T cells genetically modified to express a CAR may be provided to the subject by administering the T cells genetically modified to express a CAR or by generating the T cells genetically modified to express a CAR in the subject. The methods of the disclosure may further comprise administering to the subject an antigen or a variant thereof, or a polynucleotide encoding an antigen or a variant thereof, wherein the T cells genetically modified to express a CAR are targeted to the antigen. In one particularly preferred embodiment, the polynucleotides administered according to the present disclosure are RNA. | 2022-04-28 |
20220125837 | METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS - The technology relates in part to methods for controlling elimination of therapeutic cells, for example, cells that express a chimeric antigen receptor. The technology further relates to a two-step method of controlling destruction of therapeutic cells in a patient following an adverse event. The two-step system may include a rapamycin or rapamycin analog-based level of control and a second, rimiducid, level of control. The technology also relates in part to methods for cell therapy using cells that express the inducible caspase polypeptide and the rapamycin-sensitive polypeptide, where the proportion of therapeutic cells eliminated by apoptosis is related to the choice and amount of the administered ligand. | 2022-04-28 |
20220125838 | IMMUNOMODULATORY GLYCOSPHINGOLIPIDS AND METHODS OF USE THEREOF - Provided herein are a subset of alpha-galactosylceramide (alpha-GC) compounds having improved immunomodulatory activity, particularly with respect to NKT cell number and activity. Also provided herein are methods of use of such compounds, including in the modulation of NKT cells and/or activity in vivo. Further provided are combinatorial synthesis methods for generating alpha-GC compounds of specifically defined structure and thereby generating pure preparations thereof. | 2022-04-28 |
20220125839 | COMBINATION OF T-CELL THERAPY AND TARGETED THERAPY FOR TREATING THERAPY-RESISTANT MELANOMA WITH MUTATIONS IN THE BRAF GENE - Approximately 50% of melanoma patients carry a mutation in the BRAF protein. Targeted therapy with inhibitors of BRAF and the downstream pathway is very effective in these patients, but long-term benefits are limited due to the onset of therapy resistance. Previous studies demonstrated that BRAF inhibitors (BRAFi) positively affect the antitumor immune response mediated by T cells. Disclosed are methods of treating, preventing, inhibiting, reducing, and/or ameliorating a cancer and/or metastasis in a subject using an adoptive T cell therapy, the method comprising administering to the subject a BRAF inhibitor (BRAFi) (such as, for example, sorafenib, vemurafenib, dabrafenib, and/or encorafenib) and an adoptive T cell therapy, wherein administration of the BRAF inhibitor increases insulin-like growth factor II receptor (IGF2R). | 2022-04-28 |
20220125840 | BAFF-R/CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS AND USE THEREOF - Chimeric antigen receptors targeting both BAFF-R and CD19 are described as are methods for their use. | 2022-04-28 |
20220125841 | SODIUM FLUORESCEIN AS A REVERSAL AGENT FOR AN ANTI-FLUORESCEIN CAR T CELLS AND FLUORESCEIN-PHOSPHOLIPID-ETHERS OR PROFLUORESCEIN-PHOSPHOLIPID-ETHERS - Some embodiments of the methods and compositions provided herein relate to modulating signaling of anti-hapten CAR T cells, such as anti-fluorescein CAR T cells, by the use or administration of an unconjugated hapten, such as unconjugated fluorescein or a salt or derivative thereof. | 2022-04-28 |
20220125842 | TARGETING OF SRC-3 IN IMMUNE CELLS AS AN IMMUNOMODULATORY THERAPEUTIC FOR THE TREATMENT OF CANCER - The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and/or are exposed to the cells prior to administration. | 2022-04-28 |
20220125843 | MODIFIED CELLS AND METHODS OF THERAPY - Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer. | 2022-04-28 |
20220125845 | ANTI-ALPP CAR-T CELL THERAPY - The disclosure relates to anti-ALPP CAR-T cell therapies for the treatment of cancer patients having ALPP-positive cancer, including e.g., ovarian, endometrial, cervical, testicular cancers, etc. | 2022-04-28 |
20220125846 | TUMOR-ACTIVATED ALLOREACTIVE AND XENOREACTIVE T CELLS AND THEIR USE IN IMMUNOTHERAPY AGAINST CANCER - Provided are tumor-activated alloreactive or xenoreactive T cells that are active only at the tumor sites and methods for the generation of tumor-activated alloreactive or xenoreactive T cells. Also provided are methods for using these tumor-activated alloreactive or xenoreactive T cells to treat tumors and cancers. The alloreactivity or xenoreactivity of the T cells at the tumor sites leads to the killing of tumor cells and stromal cells that express mismatched HLA molecules. The lack of activity of these T cells at non-tumor locations prevents attack on normal tissues. Further related methods and products are provided. | 2022-04-28 |
20220125847 | UNIVERSAL IMMUNE CELLS FOR CANCER IMMUNOTHERAPY - Embodiments of the disclosure encompass adoptive immunotherapy related to cells expressing multiple chimeric antigen receptors (CARs). In specific embodiments, T cells express a HER2-specific CAR, an IL13Rα2-specific CAR, and an EphA2-specific CAR. In particular embodiments, the cells are utilized for cancer treatment, including for glioblastoma. | 2022-04-28 |
20220125848 | METHOD FOR TREATING OSTEOARTHRITIS WITH A COMBINATION OF MESENCHYMAL STEM CELL EXOSOMES, SYNOVIAL MESENCYMAL STEM CELLS, AND SCAFFOLDS - Disclosed herein are methods for treating osteoarthritis may be a one-step arthroscopic procedure and may include detaching synovial mesenchymal stem cells (MSCs) from the synovium using a brush device; covering articular cartilage in an affected joint with a scaffold; and placing concentrated MSC exosomes into the affected joint to stimulate differentiation of synovial MSCs into articular cartilage cells. | 2022-04-28 |
20220125849 | METHODS FOR IMPROVING COGNITIVE FUNCTION - The present disclosure relates to a method of improving cognitive function in a subject. The method includes implanting group-2 innate lymphoid cells (ILC2) in a cranium of a subject, where the ILC2 was treated with an ILC2 activator. The present disclosure further relates to a method including selecting a subject having aging-associated cognitive decline and administering to the subject an activator of innate lymphoid cell activity under conditions effective to promote innate lymphoid cell activity. The present disclosure further relates to a method of improving cognition in a subject. The method includes selecting a subject having aging-associated cognitive decline and administering to the subject a cytokine selected from the group consisting of IL-33, IL-5, IL-7, IL-25, and thymic stromal lymphopoietin. | 2022-04-28 |
20220125850 | PHARMACEUTICAL COMPOSITION FOR PREVENTING IN-STENT RESTENOSIS - The present invention relates to a pharmaceutical composition containing mesenchymal stem cells administered to a patient subjected to stenting. The present invention relates specifically to: a pharmaceutical composition for repairing and regenerating tissue, comprising mesenchymal stem cells, wherein the pharmaceutical composition is administered to a patient subjected to stenting; and the prevention of in-stent neointimal hyperplasia or in-stent restenosis with the pharmaceutical composition. | 2022-04-28 |
20220125851 | MATERIALS AND METHODS FOR BONE MARROW TRANSPLANTATION - The disclosure provides a method of preparing HSPC for bone marrow transplantation, the method comprising (a) obtaining donor hematopoietic stem and progenitor cells and (b) upregulating expression of Kruppel-like factor 6. | 2022-04-28 |
20220125852 | PROTECTION AND REGENERATION OF NEUROLOGICAL FUNCTION BY USING STEM CELLS - Disclosed are therapeutic compounds, protocols, and compositions of matter useful for treatment of neurological conditions. In one embodiment the invention teaches the treatment of chronic traumatic encephalopathy (CTE) through protecting/regenerating the endothelial by administration of cells such as stem cells. In one embodiment stem cells are administered in order to protect the endothelium from apoptosis and to preserve the blood brain barrier. In another embodiment stem cells are administered together with endothelial progenitor cells in order to regenerate neural endothelium. In other embodiments preservation of brain integrity in conditions of degeneration is accomplished by administration of stem cells and/or endothelial cells. | 2022-04-28 |
20220125853 | MATERIALS AND METHODS FOR ENHANCING BONE CELL DIFFERENTIATION - This document provides materials and methods for enhancing bone cell differentiation. For example, compositions containing an epigenetic drug, an actin modulator, and/or one or more osteogenic differentiation factors that can be used to enhance bone cell differentiation are provided. | 2022-04-28 |
20220125854 | PREPARATION AND EXTENDED CULTURE OF VASCULAR ENDOTHELIAL PROGENITOR CELL - It is a subject to provide a means of preparing highly pure vascular endothelial progenitor cells in a simple and low-cost manner. It is also a subject to provide a method for efficiently proliferating vascular endothelial progenitor cells. High-purity vascular endothelial progenitor cells are prepared by the process of differentiating pluripotent stem cells into vascular endothelial progenitor cells and purifying the vascular endothelial progenitor cells using a difference in adhesion ability between the vascular endothelial progenitor cells constituting the cell population obtained in the process and other cells. On the other hand, vascular endothelial progenitor cells are cultured and expanded in the presence of a ROCK inhibitor, a GSK-3β inhibitor, and a TGF-β receptor inhibitor in addition to basic fibroblast growth factor and epidermal growth factor. | 2022-04-28 |
20220125855 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein. | 2022-04-28 |
20220125856 | USE OF OVARIAN-DERIVED HYDROGELS FOR RESTORATION OF REPRODUCTIVE FUNCTION AND HEALTH IN WOMEN - The present disclosure provides methods for restoring reproductive health and/or fertility in a subject by delivering immature follicles to the subject using an ovarian-derived hydrogel. The present disclosure also provides methods for treating ovarian-associated diseases using ovarian-derived hydrogels or their derivatives for delivery of therapeutic agents to the subject in need thereof. The present disclosure further provides kits for restoring reproductive health and/or fertility, and kits for treating ovarian-associated diseases. | 2022-04-28 |
20220125857 | PROCESS OF PRODUCING CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITION FROM KRILL EXTRACTS CONTAINING HIGH LEVEL OF FREE FATTY ACIDS - It is provided processes for generating a therapeutic concentrated phospholipid composition from raw krill oil containing high content of free fatty acids. Particularly it is provided a process producing a concentrated phospholipid composition comprising the steps of: fractionating a raw hill oil (RKO) containing at least 7% of free fatty acids (FFA) obtaining a fraction enriched in phospholipids and an undesired layer; and separating said fraction enriched in phospholipids from the undesired layer, producing the therapeutic concentrated phospholipid composition with a yield of at least 30%. | 2022-04-28 |